MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-13-2025
VolitionRx Limited EBITDA 2011-2025 | VNRX
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA VolitionRx Limited
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -25.9 M | -34.8 M | -30.8 M | -27.4 M | - | -15.4 M | -17.3 M | -14.2 M | -12.1 M | -9.77 M | -5.81 M | -4.18 M | 70 K | -13 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 70 K | -34.8 M | -15.2 M |
Quarterly EBITDA VolitionRx Limited
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -5.27 M | - | - | - | -8.12 M | - | - | - | -8.77 M | - | -7.31 M | -7.65 M | -7.45 M | - | -6.85 M | -5.43 M | -5.86 M | - | -3.98 M | -4.85 M | -5.69 M | - | -3.67 M | -3.81 M | -3.82 M | - | -3.97 M | -4.25 M | -4.47 M | - | -3.5 M | -3.22 M | -3.25 M | - | -3.25 M | -2.82 M | -2.42 M | - | -2.8 M | -1.93 M | -2.31 M | - | -1.66 M | -987 K | -1.21 M | - | -817 K | -975 K | -871 K | - | -769 K | -862 K | -769 K | - | 77.6 K | 47.6 K | 23.9 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 77.6 K | -8.77 M | -3.47 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Diagnostics research industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aspira Women's Health
AWH
|
-32.5 M | - | -6.19 % | $ 10.5 M |  USA |
 |
Biocept
BIOC
|
-30.3 M | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
-21.1 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-25.8 M | - | - | $ 9.42 M |  Israel |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
DexCom
DXCM
|
784 M | $ 64.79 | 2.0 % | $ 25 B | USA |
 |
Brainsway Ltd.
BWAY
|
-5 M | $ 17.23 | 1.5 % | $ 99.4 M | Israel |
 |
Burning Rock Biotech Limited
BNR
|
-749 M | $ 21.15 | 11.37 % | $ 233 M |  China |
 |
Enzo Biochem
ENZ
|
-11.1 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
-757 M | $ 101.24 | 0.04 % | $ 18.8 B | USA |
 |
Biomerica
BMRA
|
-5.05 M | $ 2.31 | 2.01 % | $ 5.31 M | USA |
 |
BioNano Genomics
BNGO
|
-90 M | $ 1.69 | -1.74 % | $ 2.15 M | USA |
 |
Akumin
AKU
|
70.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Co-Diagnostics
CODX
|
-41.5 M | $ 0.36 | -0.39 % | $ 10.6 M | USA |
 |
Guardant Health
GH
|
-401 M | $ 104.81 | -0.39 % | $ 12.9 B | USA |
 |
Celcuity
CELC
|
-113 M | $ 98.24 | -0.25 % | $ 3.88 B | USA |
 |
DarioHealth Corp.
DRIO
|
-55.7 M | $ 11.75 | -0.47 % | $ 333 M | Israel |
 |
Heska Corporation
HSKA
|
-6.33 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-20.2 M | - | -20.0 % | $ 1.06 M | USA |
 |
ICON Public Limited Company
ICLR
|
1.59 B | $ 185.09 | 2.99 % | $ 15.3 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
1.26 B | $ 733.11 | 0.57 % | $ 60.5 B | USA |
 |
Danaher Corporation
DHR
|
5.58 B | $ 228.08 | 1.74 % | $ 167 B | USA |
 |
Illumina
ILMN
|
-479 M | $ 128.88 | 0.12 % | $ 20.5 B | USA |
 |
Anixa Biosciences
ANIX
|
-13.8 M | $ 4.25 | -3.41 % | $ 136 K | USA |
 |
Laboratory Corporation of America Holdings
LH
|
1.73 B | $ 267.33 | -0.14 % | $ 22.4 B | USA |
 |
Lantheus Holdings
LNTH
|
522 M | $ 58.6 | -0.81 % | $ 4.06 B | USA |
 |
Accelerate Diagnostics
AXDX
|
-12.3 M | - | -61.36 % | $ 2.46 M | USA |
 |
Medpace Holdings
MEDP
|
475 M | $ 589.45 | 0.25 % | $ 18.2 B | USA |
 |
Mettler-Toledo International
MTD
|
50.4 M | $ 1 457.09 | -0.75 % | $ 30.9 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
-62.3 M | $ 7.06 | -0.03 % | $ 640 M | USA |
 |
ENDRA Life Sciences
NDRA
|
-10.8 M | $ 5.81 | -1.43 % | $ 3.12 M | USA |
 |
NeoGenomics
NEO
|
-53 M | $ 12.02 | -0.04 % | $ 1.52 B | USA |
 |
Neogen Corporation
NEOG
|
-942 M | $ 5.91 | -0.25 % | $ 1.28 B | USA |
|
Biodesix
BDSX
|
-28.7 M | $ 7.79 | - | $ 1.01 B | USA |
 |
National Research Corporation
NRC
|
40.2 M | $ 16.27 | -3.1 % | $ 399 M | USA |
 |
Natera
NTRA
|
-524 M | $ 237.72 | 1.48 % | $ 23.4 B | USA |
 |
Invitae Corporation
NVTA
|
47.2 M | - | - | $ 21.2 M | USA |
 |
Castle Biosciences
CSTL
|
24.7 M | $ 39.24 | 0.31 % | $ 1.09 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.84 B | $ 184.06 | 0.16 % | $ 20.4 B | USA |
 |
Fulgent Genetics
FLGT
|
-49 M | $ 28.38 | -0.49 % | $ 858 M | USA |
 |
Organovo Holdings
ONVO
|
-12.4 M | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
499 K | - | -16.95 % | $ 1.54 M | USA |
 |
Pacific Biosciences of California
PACB
|
-323 M | $ 2.33 | 4.69 % | $ 591 M | USA |
 |
PerkinElmer
PKI
|
775 M | - | -0.91 % | $ 14.7 B | USA |
 |
Psychemedics Corporation
PMD
|
-1.22 M | - | -1.84 % | $ 15.3 M | USA |
 |
Precipio
PRPO
|
-6.4 M | $ 24.56 | 8.81 % | $ 31.9 M | USA |
 |
Personalis
PSNL
|
-57.3 M | $ 10.09 | 4.18 % | $ 598 M | USA |
 |
RadNet
RDNT
|
242 M | $ 79.11 | -1.13 % | $ 5.78 B | USA |
|
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Global Cord Blood Corporation
CO
|
652 M | - | - | $ 399 M | China |